Human Milk Oligosaccharides (HMO) Milk Powder Market Size, Share, Opportunities, And Trends By Type (2'-Fucosyllactose (2'FL), 3'-Fucosyllactose (3'FL), 3'-Sialyllactose (3'SL), 6'-Sialyllactose (6'SL), Lacto-N-tetraose (LNT), Lacto-N-neotetraose (LNnT), Difucosyllactose (DFL)), By Application (Infant Formula, Dietary Supplements, Functional Foods and Beverages, Cosmetics), By Distribution Channel (Online Retailers, Supermarkets/Hypermarkets, Specialty Stores, Convenience Stores), And By Geography – Forecasts From 2025 To 2030

The Human Milk Oligosaccharides (HMO) Milk Powder Market is set to witness robust growth at a CAGR of 11.16% during the forecast period to be worth US$ 5.409 billion in 2030 from US$ 3.187 billion in 2025.

The Human Milk Oligosaccharides (HMO) Milk Powder Market is experiencing robust demand due to the growing approval for the HMO milk powder from regulatory authorities. In August 2024, DSM-Firmenich announced the successful approval of its human milk oligosaccharide, 3-fucosyllactose (3-FL) and lacto-N-fucopentaose I/2'-fucosyllactose (LNFP-I/2'-FL) mixture. This approval is for the novel food ingredients in the United Kingdom and European Union. This is a significant development, opening up new possibilities for further product innovation and development. Additionally, the increased awareness about HMOs, such as improved gut health and immune support, is fueling market growth.

Market Trends:

• HMO Approval in China for Infant Formula: Human milk oligosaccharides (HMOs), a key component of breast milk after lactose and lipids, were approved for use in various infant formula types in China in October 2023. This regulatory change has accelerated market growth, with companies like Novonesis, a leader in HMO development for the U.S. and Europe, now expanding into China. Other notable players include International Flavours and Fragrance (IFF), DSM-Firmenich, and local producer Mengniu.
• North America: The HMO market is driven by major U.S.-based companies leading innovation in products such as infant formula, dietary supplements, functional foods, and beverages.
• Asia-Pacific: Rapid urbanization and growing incomes in countries like China, India, and Southeast Asia are driving market expansion. Increased awareness of HMO milk powder benefits, coupled with rising disposable incomes, is fueling demand for premium alternatives to traditional food supplements.

Some of the major players covered in this report include BASF SE , Abbott Laboratories, Chr. Hansen Holding A/S, DuPont de Nemours, Inc., DSM-Firmenich, Royal FrieslandCampina N.V., ZuChem, Inc., Inbiose NV, among others.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2022 to 2024 & forecast data from 2025 to 2030
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

Human Milk Oligosaccharides (HMO) Milk Powder Market Segmentation:

By Type

• 2'-Fucosyllactose (2'FL)
• 3'-Fucosyllactose (3'FL)
• 3'-Sialyllactose (3'SL)
• 6'-Sialyllactose (6'SL)
• Lacto-N-tetraose (LNT)
• Lacto-N-neotetraose (LNnT)
• Difucosyllactose (DFL)

By Application

• Infant Formula
• Dietary Supplements
• Functional Foods and Beverages
• Cosmetics

By Distribution Channel

• Online Retailers
• Supermarkets/hypermarkets
• Specialty Stores
• Convenience Stores

By Region

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

---

1. EXECUTIVE SUMMARY 

2. MARKET SNAPSHOT

2.1. Market Overview

2.2. Market Definition

2.3. Scope of the Study

2.4. Market Segmentation

3. BUSINESS LANDSCAPE 

3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities 

3.4. Porter’s Five Forces Analysis

3.5. Industry Value Chain Analysis

3.6. Policies and Regulations 

3.7. Strategic Recommendations 

4. TECHNOLOGICAL OUTLOOK 

5. HUMAN MILK OLIGOSACCHARIDES (HMO) MILK POWDER MARKET BY TYPE

5.1. Introduction

5.2. 2'-Fucosyllactose (2'FL)

5.3. 3'-Fucosyllactose (3'FL)

5.4. 3'-Sialyllactose (3'SL)

5.5. 6'-Sialyllactose (6'SL)

5.6. Lacto-N-tetraose (LNT)

5.7. Lacto-N-neotetraose (LNnT)

5.8. Difucosyllactose (DFL)

6. HUMAN MILK OLIGOSACCHARIDES (HMO) MILK POWDER MARKET BY APPLICATION

6.1. Introduction

6.2. Infant Formula

6.3. Dietary Supplements

6.4. Functional Foods and Beverages

6.5. Cosmetics

7. HUMAN MILK OLIGOSACCHARIDES (HMO) MILK POWDER MARKET BY DISTRIBUTION CHANNEL

7.1. Introduction

7.2. Online Retailers

7.3. Supermarkets/hypermarkets

7.4. Specialty Stores

7.5. Convenience Stores

8. HUMAN MILK OLIGOSACCHARIDES (HMO) MILK POWDER MARKET BY GEOGRAPHY

8.1. Introduction

8.2. North America

8.2.1. USA

8.2.2. Canada

8.2.3. Mexico

8.3. South America

8.3.1. Brazil

8.3.2. Argentina

8.3.3. Others

8.4. Europe

8.4.1. United Kingdom

8.4.2. Germany

8.4.3. France

8.4.4. Spain

8.4.5. Others

8.5. Middle East and Africa

8.5.1. Saudi Arabia

8.5.2. UAE

8.5.3. Others

8.6. Asia Pacific

8.6.1. China

8.6.2. Japan

8.6.3. India

8.6.4. South Korea

8.6.5. Taiwan

8.6.6. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Competitive Dashboard

10. COMPANY PROFILES

10.1. BASF SE  

10.2. Abbott Laboratories 

10.3. Chr. Hansen Holding A/S 

10.4. DuPont de Nemours, Inc.

10.5. DSM-Firmenich 

10.6. Royal FrieslandCampina N.V.  

10.7. ZuChem, Inc. 

10.8. Inbiose NV 

10.9. Glycosyn LLC 

10.10. Kirin Holdings Company, Limited (Kyowa Hakko Bio)  

11. APPENDIX

11.1. Currency 

11.2. Assumptions

11.3. Base and Forecast Years Timeline

11.4. Key benefits for the stakeholders

11.5. Research Methodology 

11.6. Abbreviations

BASF SE 

Abbott Laboratories

Chr. Hansen Holding A/S

DuPont de Nemours, Inc.

DSM-Firmenich

Royal FrieslandCampina N.V. 

ZuChem, Inc.

Inbiose NV

Glycosyn LLC

Kirin Holdings Company, Limited (Kyowa Hakko Bio)